MAX HEALTHCARE INS LTD (543220) — Latest Corporate Announcements
₹856.05
₹-9.90 (-1.14%)
Market Cap
₹83,320.22 Cr
P/E Ratio
57.41
52W Range
₹842.05 – ₹1221.9
Corporate Actions & Regulatory Filings
Max Healthcare Institute Ltd - 543220 - Announcement under Regulation 30 (LODR)-Credit Rating
Max Healthcare Institute Ltd - 543220 - Announcement under Regulation 30 (LODR)-Credit Rating
Max Healthcare Institute Ltd - 543220 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Max Healthcare Institute Ltd - 543220 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Max Healthcare Institute Ltd - 543220 - Closure of Trading Window
Max Healthcare Institute Ltd - 543220 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Max Healthcare Institute Ltd - 543220 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Max Healthcare Institute Ltd - 543220 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Max Healthcare Institute Ltd - 543220 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Max Healthcare Institute Ltd - 543220 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Max Healthcare Institute Ltd - 543220 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Max Healthcare Institute Ltd - 543220 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Max Healthcare Institute Ltd - 543220 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Max Healthcare Institute Ltd - 543220 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
To consider and approve the financial results for the quarter ended Jun 30, 2026
To consider and approve the financial results for the quarter and financial year ended March 31, 2026 and dividend
To consider and approve the financial results for the period ended December 31, 2025
To consider and approve the financial results for the quarter and half year ended September 30, 2025
To consider and approve the financial results for the period ended Jun 30, 2025
To consider and approve the financial results for the quarter and financial year ended March 31, 2025 and dividend
Financial Results (Quarterly & Annual)
| Quarter / Period | Meeting / Outcome Date | Status | Filing Details |
|---|---|---|---|
| Quarter Ended 30-Jun-2026 (Q1 FY27) | 13-Aug-2026 | Declared | To consider and approve the financial results for the quarter ended Jun 30, 2026 |
| Year Ended 31-Mar-2026 (Q4 FY26) | 21-May-2026 | Declared | To consider and approve the financial results for the quarter and financial year ended March 31, 2026 and dividend |
| Quarter Ended 31-Dec-2025 (Q3 FY26) | 05-Feb-2026 | Declared | To consider and approve the financial results for the period ended December 31, 2025 |
| Quarter Ended 30-Sep-2025 (Q2 FY26) | 14-Nov-2025 | Declared | To consider and approve the financial results for the quarter and half year ended September 30, 2025 |
| Quarter Ended 30-Jun-2025 (Q1 FY26) | 13-Aug-2025 | Declared | To consider and approve the financial results for the period ended Jun 30, 2025 |
| Year Ended 31-Mar-2025 (Q4 FY25) | 20-May-2025 | Declared | To consider and approve the financial results for the quarter and financial year ended March 31, 2025 and dividend |
| Quarter Ended 31-Dec-2024 (Q3 FY25) | 30-Jan-2025 | Declared | To consider and approve the financial results for the period ended December 31, 2024 |
| Quarter Ended 30-Sep-2024 (Q2 FY25) | 05-Nov-2024 | Declared | To consider and approve the financial results for the period ended September 30, 2024 |
| Quarter Ended 30-Jun-2024 (Q1 FY25) | 01-Aug-2024 | Declared | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Year Ended 31-Mar-2024 (Q4 FY24) | 22-May-2024 | Declared | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Quarter Ended 31-Dec-2023 (Q3 FY24) | 31-Jan-2024 | Declared | To consider and approve the financial results for the period ended December 31, 2023 |
| Quarter Ended 30-Sep-2023 (Q2 FY24) | 06-Nov-2023 | Declared | To consider and approve the financial results for the period ended September 30, 2023 |
Track Related Peer Equities
Related Research Guides & Regulatory Playbooks
Frequently Asked Questions about MAX HEALTHCARE INS LTD BSE Disclosures
What is the latest BSE announcement by MAX HEALTHCARE INS LTD?
The latest BSE disclosure by MAX HEALTHCARE INS LTD (MAXHEALTH), filed on 2026-10-09T22:25:58, is: "Max Healthcare Institute Ltd - 543220 - Announcement under Regulation 30 (LODR)-Credit Rating". Bsenexus tracks every official filing for MAX HEALTHCARE INS LTD with AI-powered summaries on its announcements feed.
When is MAX HEALTHCARE INS LTD's next board meeting?
No upcoming board meeting is currently tracked for MAX HEALTHCARE INS LTD. Companies disclose meeting intimations under SEBI LODR, and scheduled dates appear on the Bsenexus Results Calendar.
When does MAX HEALTHCARE INS LTD declare quarterly results?
Under SEBI (LODR) Regulation 33, listed companies submit quarterly unaudited results within 45 days of the quarter ending, and annual audited figures within 60 days. MAX HEALTHCARE INS LTD's recent results history is tabulated above. Track scheduled board meetings on the Bsenexus Results Calendar.